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Platinum-based drugs have over the years been administered in the treatment of tumours. 
Unfortunately, platinum resistance and the severe side effects associated with the treatments has 
necessitated the research for new anti-cancer drugs. Ruthenium(II) and Ruthenium(III) complexes 
have shown promise as useful alternative anticancer agents. The lead candidates include the Ru(II) 
complex RAPTA-C, a ruthenium(II)-arene complex [Ru(η6-p-cymene)Cl2(1,3,5-triaza-7-
phosphaadamantane)]  and the Ru(III) complex NAMI-A [imidazoleH][trans-Ru(imidazole) 
(dimethyl sulfoxide)Cl4]. Both compounds have shown potent cytotoxic activity in several primary 
human tumor models. Unfortunately, NAMI-A could not advance in clinical evaluations due to 
limited efficacy in vivo, while the clinical evaluation of RAPTA-C is unknown. Therefore, there 
is a need for novel cancer therapeutics that have high biological activity, are relatively easy to 
synthesize, and can readily be modified. This work focuses on the use of 2-acetylpyridine and 2-
pyridinecarboxaldehyde for the synthesis, characterization, and preliminary evaluation of 
derivatives of both the RAPTA-C and NAMI-A anticancer complexes containing Schiff base 
ligands. Here, the results of the synthesis of these compounds and their subsequent characterization 
using 1H NMR, MS, fluorescence and UV-Vis spectroscopies are presented. 
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CHAPTER I: INTRODUCTION 
Introduction to Cancer 
According to the World Health Organization (WHO), cancer is a group of diseases 
characterized by the uncontrolled growth of abnormal cells with the tendency to spread to other 
parts of the body.1 Cancer development and metastasis, the spread of cancer cells, occurs in 
several stages and often may arise from the dysfunction of several regulatory features that 
ensures proper functioning of the cells.2 Cancer is one of the leading causes of death globally,1,3 
accounting for 13% of all deaths worldwide. It is estimated that about 9.6 million deaths would 
be recorded in 2018 while the number of new cases for 2018 was approximately 14.1 million.1 
Despite the over $1.16 trillion annual economic cost for the treatment of cancer,1 there is no 
current therapeutic method that can provide a complete treatment of most forms of proliferated 
tumors in humans.3 This necessitates the development of novel chemotherapeutic agents for the 
treatment of cancer.   
Platinum-based Anticancer Drugs 
Since the discovery of the bioactivity of cis-diamminedichloroplatinum(II), commonly 
known as cisplatin in 1965 by Dr. Rosenberg et al.4,5 and its subsequent approval by the U.S 
Food and Drugs Administration (FDA) in 1978,6 metallochemotherapeutics, especially platinum-
based compounds have been successfully used for treatment of many neoplastic conditions. 
Cisplatin is the most common antineoplastic chemotherapeutic agent used to treat several types 
of cancer, including ovarian, cervical, stomach, bladder, head, and neck.5 The use of cisplatin as 
a chemotherapeutic agent greatly improved the survival chances for many cancer patients. For 
example, the drug increased the rate of cure of testicular cancer from less than 10% to 90% in 
modern oncotherapy6 and almost 100% when the cancer cells are in stage 1 of development5 
where the cancer has attacked tissues next to the testicle, but not lymph nodes, or more distant 
2 
cells in the body.9 In North America and Europe, it is estimated that more than one million 
cancer patients are on cisplatin treatments.6  
Cisplatin treats cancer cells mainly by cross-linking deoxyribonucleic acid (DNA) and 
inhibiting transcription and replication. 6 The drug first enters the cell by the copper transporter, 
CTR14,7 and undergoes ligand exchange by exchanging one or both chloride ligand with 
molecules of water (Figure 1).6 
           
Figure 1. Simplified mechanism of action of cisplatin. Adapted with permission13  
 
The resulting platinum(II) aqua complexes formed are strong electrophiles that are highly 
reactive towards several biological ligands. The N7 position of the purine base guanine is 
strongly nucleophilic in nature. Hence, cisplatin readily binds to DNA at that position and may 
yield bifunctional adducts with loss of both chloride ligands or water. The main product formed 
from cisplatin−DNA interaction is the intrastrand 1,2-d(GpG) cross-link as shown in Figure 1. 
This mode of action of cisplatin triggers apoptosis.6 
Unfortunately, the use of cisplatin to treat tumors is associated with high toxicity and 
severe side effects due to nonselective binding to DNA.5 These severe side effects include 
nephrotoxicity, neurotoxicity, ototoxicity or toxicity to the ear, nausea, vomiting and in some 
3 
cases permanent hearing loss and acute renal failure.4,5 It is estimated that only 1% of 
intravenously administered cisplatin enters the cell nucleus. It has been reported that about 60% 
of cisplatin administered reacts with glutathione (GSH) to form the product [Pt(GS)2].
4 This 
product, however does not contribute to the inactivation of the drug, rather, the GSH−cisplatin 
adduct inhibits the selenoenzyme thioredoxin reductase (TrxR) and induces redox reactions 
within the cell. This behavior has been associated with nephrotoxicity and hepatic dysfunction. 
Therefore, the off-target toxicity of cisplatin is partly attributed to redox agitations within the 
cell.4 This mechanism of action of cisplatin however induces platinum resistance.6  
To overcome the difficulties associated with cisplatin, the ligands around the metal have 
been modified to produce Carboplatin and Oxaliplatin which are second and third generation 
compounds of Pt used to treat tumors (Figure 2).4,10 These modifications of the ligands around 
the platinum affect the adducts the complex forms with biological tissues. Carboplatin was 
approved by the FDA in 1989 and Oxaliplatin was approved in 2002. Carboplatin is used for the 
treatment of ovarian cancers whereas Oxaliplatin is used to treat colon and rectal cancers.4 
Carboplatin and oxaliplatin are both considered to exhibit mechanisms of action identical to that 
of cisplatin, related to attack on DNA. Carboplatin possesses a relatively stable chelating 1-
cyclobutanedicarboxylato (CBDCA) ligand as its leaving group.6  
 
      
Figure 2. The different generations of platinum anticancer compounds.   
4 
Carboplatin however, gives reduced side effects  compared to cisplatin6,11 which is 
attributed to a change in reactivity at the metal center due to the chelating nature of the leaving 
group ligand and, the potential conformation that this ligand assumes.11 Oxaliplatin, on the other 
hand,  also features a chelating oxalate leaving group ligand together with a chelating R,R-
diaminocyclohexane (DACH) nonleaving group ligand.11 This drug shows improved 
performance over cisplatin toward colorectal cancers.6,11 The exceptional activity of Oxaliplatin 
in the treatment of colon and rectal cancers is attributed to the ability of the drug to act as a 
substrate for organic cation transporters (OCTs), which are overexpressed in a large number of 
colon cancer patients.11 However, cisplatin remains a chemotherapeutic agent of choice with 
widespread use.5 Three other platinum compounds shown in Figure 3, nedaplatin, heptaplatin 
and lobaplatin, are widely employed in Asia.4  
                  
 
Figure 3. Structures of Platinum compounds most commonly used in Asia.  
 
Nedaplatin finds clinical use in China whilst heptaplatin and lobaplatin are used in South 
Korea and Japan respectively.5 Nedaplatin was  discovered and developed in Japan, which since 
1995 ,together with China are the only countries where the drug has attained clinical approval.11 
Like cisplatin and carboplatin, this drug has cis-ammine nonleaving group ligands. The chelating 
leaving group ligand is glycolate, which enhances water solubility to 10 mg mL-1 compared to 
cisplatin which has a solubility of 2.5 mg mL-1.11 Though clinical exploration of the drug is still 
5 
on-going, the drug is commonly used to treat cancer of the head and neck and esophagus as well 
as small cell lung cancer and non -small cell lung cancer.11 
Heptaplatin was developed in Korea by the Sunkyong Industry Research Center and 
entered clinical trials in the 1990s. The drug was subsequently approved for clinical use by the 
Korean Food and Drug Administration in 1999. The compound has a malonate chelating leaving 
group ligand and a chelating 2-(1-methylethyl)-1,3-dioxolane-4,5-dimethanamine nonleaving 
group. The nonleaving group ligand assumes a seven-membered chelate ring conformation 
giving the generic name of the drug. Heptaplatin is commonly used for the treatment of gastric 
cancer. 11 
Lastly, lobaplatin was first developed by ASTA Medica in Germany while clinical 
evaluations of the drug were initially carried out in Europe, the United States, Australia, Brazil, 
and South Africa all examined its efficacy in patients of varying cancers. Clinical approval for 
medical treatments was only obtained in China in 2010.11 Lobaplatin is considered a derivative 
of heptaplatin with a cyclobutane ring fused to the seven-membered chelate ring compared to the 
functionalized dioxolane in heptaplatin. The drug is used most commonly for the medical 
treatment of chronic myelogenous leukemia but is also administered in patients with small cell 
lung cancer and metastatic breast cancer.11 
Complexes of metals such as Pt(II), Pt(IV), and Ru(II), exhibit slow ligand kinetics which 
is comparable to many cellular division processes (Figure 4). The ligand exchange mechanism 
of these metals depends on the metals and the ligands bonded to them. Square planar compounds 
of Pt(II) undergo a ligand exchange by an associative process where the incoming ligand 
coordinates as fifth ligand after which one of the original ligands dissociates. However, 
octahedral Ru(II) complexes initially lose a ligand to form a five-coordinate intermediate after 
which the other ligand bonds to the compound.10 
6 
 
Figure 4. Rate of aqueous ligand exchange of various metal cations.  
Adapted with permission9 
 
Ruthenium Anticancer Compounds    
To overcome the limitation of platinum-based chemotherapeutics, ruthenium compounds 
have been investigated for the development as anticancer drugs.3 Ru(II) compounds exhibit 
ligand exchange kinetics similar to Pt(II) complexes.17 These complexes exhibit ligand exchange 
kinetics in water at a rate comparable to the kinetics of cellular reproduction (mitosis).18 It is 
therefore suggested that Ru ions could remain inside the cell throughout the entire cell lifespan.12 
Initially, the ruthenium complex undergoes aquation where a chloride ligand is exchanged for 
water  forming hydrolyzed products. This suggests a selective activation mechanism for Ru-
chlorido complexes. In Ru arene complexes, the rate of hydrolysis is also influenced by the 




The higher concentration of glutathione and lower concentration of molecular oxygen in 
tumor cells renders them more acidic than normal healthy cell.12,14 This means that Ru 
complexes can be taken up as Ru(III) where they can be activated by reduction to the active 
Ru(II) oxidation states within cancer cells. This, in one proposed reason, explains why the Ru 
complexes are less toxic compared to Pt complexes.12,14 
The ammine complexes, fac-[RuCl3(NH3)3] and cis-[Ru(NH3)4Cl2] have long been found 
to be active against cancer cells.15 These two complexes were evaluated for their anticancer 
activity by Clarke in 1980.16 However, their poor aqueous solubility prevented their clinical 
use.15,6  
It is believed that both Ru(II) and Ru(III) anticancer complexes exhibit a novel 
mechanism of action that is independent of DNA binding.4 One example is the preclinical Ru(II) 
compound, [Ru(η6-p-cymene)(PTA)Cl2] (RAPTA-C; PTA = 1,3,5-triaza-7-phosphaadamantane 
(RAPTA-C) which is reported to demonstrate antitumor activity by binding two protein targets, 
thioredoxin reductase and cathepsin B.62 Thioredoxin reductase is a flavoenzyme that, together 
with thioredoxin (Trx) and reduced nicotinamide adenine dinucleotide phosphate (NADPH), 
make and maintains cellular redox state. Cathepsin B is also a cysteine peptidase capable of 
degrading components of the extracellular matrix in diseases such as muscular dystrophy and 
rheumatoid arthritis. It has been proposed that cathepsin B function together with other cysteine 
cathepsins, in metastasis, angiogenesis, and tumor progression.3,62  
However, ruthenium(II) compound [Ru(II)(η6-biphenyl)Cl(en)]PF6 (RM175; en = 
ethylenediamine), is reported to show a strong binding preference to DNA but not sulfur- or 
nitrogen-containing biomolecules.  Unlike cisplatin, RM175 forms a distinct type of adduct with 
DNA that is more resistant to DNA repair mechanisms. Furthermore, RM175 does not 
8 
demonstrate any in vitro or in vivo cross-resistance in cisplatin-resistant A2780cis ovarian 
carcinoma, indicating a different mode of action as relative to cisplatin.  
The mechanism of the Ru(III) anticancer compounds are represented in Figure 5. 
 
                
Figure 5. Mechanism of action of RAPTA-C anticancer compounds. 
 
Lastly, ruthenium can mimic iron in binding to the serum protein, transferrin.3 
Transferrin is the main protein in the blood that binds to iron and transports it throughout the 
body. The binding behavior of ruthenium to transferrin is attributed to the fact that both iron and 
ruthenium appear in the same group on the periodic table.3  
The first ruthenium complexes that were taken through clinical trials were those 
containing the indazole ligands which were synthesized by Keppler. These are the isoelectronic 
ruthenium(III) compounds [imH]trans-[Ru(N-im)2Cl4] and [indH]trans-[Ru(N-ind)2Cl4] (im= 
imidazole, ind = indazole) which were active against several tumors models, especially against 
platinum- resistant colorectal autochthonous tumors.16   
9 
Ruthenium(II) Arene Anticancer Compounds 
In 1992, Tocher et al. proposed the idea of using arene ruthenium compounds as 
anticancer agents which were subsequently pioneered by Dyson and Sadler.12,13 Arene Ru(II) 
complexes (Figure 6) have the general formula [(η6-arene)Ru(X)(Y)(Z)], where the arene rings 
include benzene (ben), methylisopropyl benzene (cym), biphenyl (bip) and dihydroanthracene 
(dha). The ligands X and Y are either two monodentate ligands or one bidentate ligand, and Z is 
most commonly a leaving group, such as a halogen. 44,48  
  
Figure 6. The general structure of  Ru(II) arene complexes, (a)contains one bidentate ligand or 
(b) one monodentate ligand and one bidentate ligand, where A is an arene ring, and X, Y and 
Z are ligands. 
  
This synthesis of Ru arene complexes for cancer therapy has gained prominence due to 
the amphiphilic properties of the complexes. The hydrophobic arene ligand is balanced by the 
hydrophilic metal center, which can coordinate to water molecules. Additionally, the 
monodentate and bidentate ligands around the metal center form an important scaffold that can 
be modified to produce new class of compounds. These ligands around the metals are important 
for interacting with biological targets such as proteins and DNA  in chemotherapy.12,13 
In the structure of Ru(II) arene compounds, the arene moiety is considered the main 
component of arene Ru(II) complexes. The arene ring is hydrophobic, which enhances the 
permeation of Ru(II) complexes into cells as well as stabilizes the complex by establishing the 
10 
18-electron configuration of the complex.14,15,  However, the concentration of Z (Z = Cl-, Br-, I-) 
and the pH of the tumor environment are two factors that affect the hydrolysis of Ru–Z bonds. In 
the case of chlorido complexes, high extracellular chloride concentration (103 mM) prevents 
aquation outside the cell so the hydrolysed products predominantly form inside the cell. 
Intracellular  chloride ion concentration of the nucleus (4 mM) and cytoplasm (23 mM) enhance 
the exchange of the chloride ligands inside the cell. This result suggests a selective mechanism of 
activation of Ru-chlorido complexes.9, The pKa of the environment of the complex also 
determines whether the more active Ru-OH2 or the less active Ru-OH predominates.
9 pKa values 
of most aquated Ru-arene complexes are around 8, indicating that, the dominant species at 
physiological pH (7.4) in the blood are aquated products.9  
Unlike Pt(II) compounds which are square planar, Ru(II) organometallic complexes are 
typically octahedral. Two groups of organometallic ruthenium(II) complexes, the RAPTA type 
has the 1,3,5-triaza-7-phosphaadamantane (PTA) ligand whereas the ruthenium arene 
ethylenediamine RAED type contains the ethylenediamine (en) ligand. Both compounds have 
shown promising anticancer activities. The RAPTA class of compounds have the structure [(η6-
arene) RuCl2(pta)], where pta =1,3,5-triaza-7-phosphaadamantane and the RAED class also have 
the structure, [(η6-arene) Ru(en)-(Cl)]+ where, arene = p-cymene, biphenyl, tetrahydroanthrance 
and en = ethylenediamine.15 The RAPTA class of compounds show low cytotoxicity in vitro but 
exhibit antimetastatic properties. These compounds do not show selective in vitro binding to 
DNA, proteins or RNA but inhibit cell growth by inducing apoptosis through G2/M disruption.
10 
The G2 phase is a period in the cell cycle characterized by protein synthesis and rapid cell growth 
to prepare the cell for mitosis. 
The RAED class of compounds however, show the ability to bind to DNA and form 
adducts with guanine and exhibit potent cytotoxicity in vitro interaction with DNA.3 
11 
Two prominent examples of the RAPTA and RAED types of Ru(II) arene compounds are 
RAPTA-C and RM175 (Figure 7).49  
 
Figure 7. RAPTA-C and RM175 compounds. 
 
RAPTA-C is a piano-stool ruthenium(II) arene complex developed by the Dyson group which 
has an amphiphilic PTA ligand, two labile chloride ligands, and a η6-coordinated arene.50 The 
PTA ligand does not exhibit high sterical properties and is believed to enhance water solubility 
of RAPTA-C.45,51 
 Like cisplatin and other metal-based anticancer drugs, the first step in the mechanism of 
action of RAPTA-C is believed to be ligand exchange with water molecules within the cells. 
RAPTA-C undergoes rapid hydrolysis of a Ru–Cl bond comparable to the ligand exchange 
kinetics of cisplatin in  buffered water (1.62 x 10-5 s-1). The compound exchanges one or two 
chloride ligands (Figure 5) with water and subsequently loses the aqua ligand allowing the 
molecule to bind to its target.  
At low intracellular chloride concentrations of 4–5 mM, the most commonly formed 
product is the mono-aquated complex, [Ru(p-cymene)Cl(H2O)(PTA)]
+. At a 100 mM chloride 
ion concentration similar to that of blood, hydrolysis of Ru–Cl bond is not observed. RAPTA-C 
12 
is therefore, considered a pro-drug that requires to be activated in its di-chlorido form just like 
cisplatin.14,15 
Preliminary in vitro studies with RAPTA-C  using TS/A mouse mammary 
adenocarcinoma cells did not show significant activity with IC50 greater than 300 µM. Similarly, 
studies with non-cancerous epithelial (HBL-100) cell lines also yielded IC50 values ranging from 
66 to over 300 µM. Further investigation using mice however, showed that RAPTA-C inhibited 
tumor growth by about 75%.16,17 Analyses of the treated tumor found strong anti-angiogenic 
properties of the compound. That is, RAPTA-C is able to inhibit the formation of new blood 
vessels from pre-existing ones. 
In a study involving cisplatin and RAPTA-C, despite cisplatin and RAPTA-C having 
similar leaving group chloride ligand and similar ligand exchange kinetics in water, RAPTA-C 
appeared more inert to extracellular reactions compared to cisplatin.18 This study further revealed 
that, RAPTA-C was found to predominantly bind albumin, a small molecule transporter in blood 
plasma.18 This result may indicate a selective mechanism of action of RAPTA-C. 
The RAED complex RM175, [Ru(biphenyl)Cl(en)]+ was amongst the first ruthenium(II) 
complexes that were investigated for anticancer activity. This organometallic complex was 
developed by the Sadler group in 2001.19,20 Biological studies of the complex has revealed 
binding to DNA in addition to other cellular targets such as the inhibition of matrix 
metalloproteinase-2 (MMP-2). MMP-2 is an important class of metalloproteinases that 
contribute to tumor growth by controlling the microenvironment of the tumor and uses signaling 
pathways to modulate cell growth and angiogenesis.19, 21 
Similar to RAPTA-C, RM175 is activated by ligand exchange of a chloride ligand with 
water at the monodentate site. The aquation reaction facilitates covalent binding to the N7 of 
13 
guanine in the DNA double helix. The arene moiety in this complex enhances hydrophobic 
interactions between  RM175 and DNA by arene-intercalation between DNA base pairs.21 
 RM175 also exhibits anticancer activity by altering the processes of cell invasion and migration. 
The ruthenium complex is reported to be more potent against metastases over primary tumors, 
and the efficacy is found to be affected by the amount of the administered dose. It is reported that 
a dose of 10 mg/kg/day resulted in an 85–95% reduction in metastatic mass, but only a 70% 
reduction was observed at a lower dose of 7.5 mg/kg/day.22  RM175 is also reported to exhibit 
elevated response towards cytotoxicity and reduced cell viability when human serum albumin 
(HSA) in ratios from 1:1 to 1:10 was used to supplement the dose. Therefore, it has been 
suggested that the  efficacy of RM175 may be greater in vivo than in vitro.19,22 
Currently, the leading Ru(II) compound for therapeutic development is TLD1433 
(Figure 8) which  has entered phase I/2a of clinical trials for the treatment of nonmuscle invasive 
bladder cancer treatment with photodynamic therapy (PDT).17 PDT involves the activation of a 
photosensitizer drug by a specific wavelength of light. This subsequently causes cell destruction 
due to generation of the free radicals that can further produce reactive oxygen species (ROS) 
and/or singlet oxygen. TLD1433 contains π-expansive organic chromophores attached to 1, 10-
phenanthroline ligand. The compound is characterized by low-lying triplet intraligand excited 
states with prolonged lifetimes ranging from tens to hundreds of microseconds. This makes it  
sensitive to trace oxygen and other quenchers and promotes the generation of cytotoxic ROS,  





Figure 8. The structure of the Ru(II) complex TLD1433.       
              
Thesis Research 
Despite the many side effects associated with the use of platinum compounds in cancer 
therapy, clinical treatments rely heavily on these drugs as there are no better alternatives yet. 
This research focuses on the design and synthesis of novel ruthenium compounds that will be 
evaluated for their anticancer activity. The targeti compounds will be derivatives of the RAED 
family of Ru(II) complexes containing modular Schiff base ligands. 
Schiff bases, named after Hugo Schiff, are formed when primary amine reacts with an aldehyde 
or a ketone under specific conditions. Schiff bases are versatile compounds that can easily be 
modified.34 In terms of structure, a Schiff base, also called imine or azomethine (-C=N-), is a 
nitrogen analogue of an aldehyde or ketone. Schiff bases have achieved prominence in medicinal 
and pharmaceutical fields due to a broad spectrum of biological activities like anti-inflammatory, 
analgesic, antimicrobial, and anticancer activities.34,35.  
The first part of the proposed work involves the syntheses of Schiff bases (Figure 9) by 
the reaction of aniline, 4-ferrocenyl aniline, and amino ferrocene with 2-acetylpyridine and 2-
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pyridinecarboxaldehyde respectively. The ligands were designed to include ferrocene given its 





Figure 9. Synthetic routes of the target Schiff base ligands.     
 
Ferrocenyl compounds such as aminoferrocenes have been investigated on human normal 
and cancer cells and have shown low toxicity, significant stability and lipophilicity, and unique 
electrochemical behavior.31 This has led to increasing research into the use of ferrocene-
containing compounds for medicinal applications.31 The Fe(II) core of ferrocene potentiates the 
generation of toxic ROS. The enhancement of the lipophilicity of organic drugs modulates the 
adsorption, distribution, metabolism, excretion, and toxicity properties of the original organic 
compounds that are modified.31 For example, ferroquine which is a ferrocene derivative of 
chloroquine, is active against chloroquine-resistant Plasmodium falciparum strains where 
chloroquine is inactive.  
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Once the Schiff base ligands have been prepared and characterized, (CHAPTER TWO) 
they will be coordinated to Ru to make new complexes (CHAPTER THREE) and finally 
preliminary evaluations of the interactions between the complexes and the serum protein albumin 
will be conducted (CHAPTER FOUR). The compounds will be characterized using proton 
nuclear magnetic resonance spectroscopy (1H NMR), elemental analysis, Ultra Violet/Visible 
spectroscopy (UV/Vis), and electrospray ionization high resolution mass spectrometry (ESI-
HRMS). The generic structure of the target Ru(II) compounds in this research work are given 
Figure 10.  
 
 






CHAPTER II: SYNTHESES AND CHARACTERIZATION OF SIX  
SCHIFF BASE LIGANDS 
Introduction  
Schiff bases are compounds that contain imine or azomethine (–C=N–) functional groups. 
These compounds are the condensation reaction products of primary amines with carbonyl 
compounds that were first synthesized by Hugo Schiff in 1864.33,34 The general reaction scheme 
for the syntheses of Schiff bases is presented in Figure 12 . 
 
 
Figure 11. The general reaction scheme for Schiff base syntheses where, R1, R2, and R3 are any 
organic chain. 
 
Schiff bases are one of the most commonly used classes of organic compounds.33 Schiff 
bases have been shown to exhibit a broad range of biological activities, including antifungal, 
antibacterial, anti-malarial, antiproliferative, anti-inflammatory, antiviral, and antipyretic 
properties.33,34 One example is fluoroquinolone (Figure 12) which was evaluated for in vitro 
antitumor activity against a murine leukemia cell line (L1210), and a human leukocytoma cell 




Figure 12. Fluoroquinolone, an anticancer Schiff base compound. 
 
Schiff bases have been used to form coordination complexes with a variety of metals.33 
Schiff bases ligands with nitrogen and oxygen donor atoms are useful chelating agents for both 
transition and non-transition metal ions.33 
Organoruthenium-based  paullone complexes, which are ruthenium(II) arene Schiff base 
complexes have also been shown to possess potent anticancer properties against the ovarian 
cancer cell line, A2780. Examples of these compounds are shown in Figure 13. 
 
Figure 13. Organoruthenium-based paullone anticancer complexes  
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Compound a in Figure 13 showed cytotoxic properties against A2870 cell with  the 
concentration at 50% inhibition (IC50) comparable to that of cisplatin. Complex b however, had 
IC50 that was 3 times lower than that of cisplatin indicating a higher activity relative to cisplatin. 
Following the efficacy of the reported N-N ligands, this part of the research deals with syntheses 
of N-N Schiff base compounds that will then be used as ligands to synthesize the ruthenium(II) 
target compounds. Six Schiff base ligands (L1 – L6) were synthesized by reaction of each of 
three primary amines – aniline, aminoferrocene, and 4-ferrocenylaniline with either 2-
acetylpyridine or 2-pyridinecarboxaldehyde (Table 1). Whereas the L1 and L2 have been 
previously reported,37 the four other Schiff base ligands (L3-L6) are novel compounds. These 
proposed ligands (Figure 14) are N-N bidentate ligands as found in RAED compounds. Since 
the discovery of ferrocene in 1951, the favorable electronic properties of ferrocene and its easy 
functionalization, makes the compound useful for wide range of applications in materials 
science.37 The stability of ferrocene in aqueous and aerobic media, and its unique electrochemical 
properties have made ferrocenyl compounds very useful molecules for biological applications. 
The anticancer properties of ferrocenyl compounds containing amine or amide groups were first 
studied in the late 1970s, using lymphocytic leukemia P-388 cells.37 
 
Ligand Pyridine Primary Amine 
L1 2-Acetylpyridine Aniline 
L2 2-Pyridinecarboxaldehyde Aniline 
L3 2-Acetylpyridine 4-Ferrocenylaniline 
L4 2-Pyridinecarboxaldehyde 4-Ferrocenylaniline 
L5 2-Acetylpyridine Aminoferrocene 
L6 2-Pyridinecarboxaldehyde Aminoferrocene 
 
Table 1. The six Schiff base ligands and the reagents that were combined to make them.  
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Figure 14. Structures of the target Schiff base ligands.  
 
It is reported that the inclusion of ferrocene into a drug scaffold improves the lipophilicity 
of organic drugs, thereby modifying the adsorption, distribution, metabolism, excretion, and 
toxicity properties of the original organic compounds. Due to the drug enhancement properties of 
ferrocene, it will be incorporated into four of the proposed Schiff bases.  
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Experimental 
General materials and methods  
The reagents utilized were purchased from Fisher Scientific, Sigma Aldrich, Cambridge 
Isotope Laboratories or Oakwood Chemical. All chemicals acquired were used as received. The 
1H NMR of the ligands were all measured with 16 scans, and field centered at 6 ppm, a sweep 
width of 20 ppm, and a delay time of 1 second. The mass spectra of the ligands were collected 
using ESI-HRMS.  
Instrumentation  
The 1H NMR spectra of the Schiff base ligands compounds were collected using a Bruker 
Avance III 400 MHz NMR spectrometer with either deuterated chloroform (CDCl3) or  
deuterated dimethylsulfoxide (DMSO-d6) as the solvent. The 
1H NMR spectra of these 
compounds were processed using the Topspin 2.1 software. The mass spectra of the ligands were 
measured using a Thermo Fischer Q Exactive mass spectrometer equipped with Thermo Q 
Exactive software which were used to process the data. The UV-vis spectra of the Schiff base 
ligands were collected using an Evolution 260 Bio Spectrophotometer equipped with a single 
cell Peltier system and a Haake DC 10 pump. The software on which the experiments were run 
was the Thermo INSIGHT software. 
N-[(Pyridin-2-yl)ethylidene]aniline (L1) 
2-Acetylpyridine (1.58 mL, 14.1 mmol) and aniline (1.29 mL, 14.2 mmol) were 
combined in a round bottom flask. Anhydrous toluene (7 mL) was then added and the reaction 
mixture heated at 120 C (reflux) for 16 hours. The reaction mixture was then allowed to cool, 
and the solvent was removed completely using the rotary evaporator. Yield:  86 % (2.39 g). 
C13H13N2
+  ESI-HRMS: m/z 197.1079, calculated 197.1079, 1H NMR δ = (400 MHz, CDCl3): 
8.59 (d, 1H,  
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Py-H6 ), 8.20 (d, 1H, Py-H3 ), 7.71 (td, 1J = 6.08 Hz, 2J = 2.17 Hz, 1H, Py-H4), 7.30 (m, 1H, Py-
H5,8 ), 7.10 (m, 3H, Ph-H9), 6.76 (d, 2H Ph-H7), 2.67 (s, 3H, CH3). 
N-[(Pyridin-2-yl)methylidene]aniline (L2) 
 First, 2-pyridinecarboxaldehyde (0.68 mL, 7.15 mmol) and aniline (0.65 mL, 7.13 
mmol) were combined in a round bottom flask. To the mixture, anhydrous toluene (7 mL) was 
then added. The reaction mixture was heated to 120 C (reflux) for 16 hours. The reaction 
mixture was then allowed to cool, and the solvent was removed completely using the rotary 
evaporator. Yield: 92 % (1.32 g). C12H11N2
+ ESI- HRMS m/z: 183.0922, Calculated: 183.0922 
1H NMR δ =  (400 MHz, CDCl3): 8.65 (dq, 
1J = 4.81 Hz, 2J = 0.84 Hz,  1H, Py-H6 ), 8.54 (s, 1H, 
CH=N), 8.14 (dt, 1J = 7.94 Hz, 2J = 1.05 Hz, 1H, Py-H3 ), 7.35 (m,  1H, Py-H4 ), 7.77 (td, 1J= 
7.70, 2J = 1.70 Hz, 1H, Py-H5 ), 7.4-6.61 (m, 5H, Ph-H7,8,9,10,11).           
4-Nitrophenylferrocene                                                                                           
A suspension of 4-nitroaniline (2.80 g, 20.0 mmol) in water (3 mL) and concentrated 
hydrochloric acid (6 mL) was cooled to 0 C. Then, sodium nitrite (1.41 g, 20.0 mmol)  in  water 
(4 mL) was added dropwise. The mixture was then stirred for 30 minutes to obtain p-
nitrobenzenediazonium chloride. In another flask, ferrocene (1.90 g, 10.0 mmol), and 
hexadecyltrimethylammonium bromide (2.01 g, 0.550 mmol) in diethyl ether (20.0 mL) was 
cooled to 0−5 C and stirred continuously. To this stirring system the prepared p-
nitrobenzenediazonium chloride suspension was then added dropwise. The reaction mixture was 
then stirred for 5 hours. The solvent was then removed using the rotary evaporator and the 
residue was washed with water (2 x 6 mL) and hexane (6 mL). The solid product obtained was 
recrystallized from petroleum ether and  4-nitrophenylferrocene was obtained as dark violet 
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plates. Yield: 89 % (2.81 g). 1H NMR   = (CDCl3, 400 MHz, ppm): 8.14 (d, 2H, C6H4), 7.78 (d, 
2H, C6H4 ), 5.00 (s, 2H, C5H4 ), 5.54 (s, 2H, C5H4 ) 4.067 (s, 5H, C5H5 ).  
4-Ferrocenylaniline 
The prepared 4-nitrophenylferrocene (0.250 g, 0.820 mmol) was dissolved in ethanol 
(5.20 mL) in a round bottom flask. Concentrated HCl (3.00 mL) and granulated tin (0.600 g, 5.05 
mmol) were then added. The reaction mixture was heated under reflux for 4.5 hours. After 
refluxing, the resulting solution was cooled to room temperature and distilled water (17.0 mL) 
was added, and the pH was adjusted to 14 with aqueous NaOH. The granulated tin was then 
filtered off and the filtrate was extracted using CH2Cl2 as the mobile phase and dried over 
anhydrous Na2SO4. The solvent was then removed on the rotary evaporator and the crude 
product was purified by column chromatography on silica gel using CH2Cl2 as the mobile phase. 
A major orange band corresponding to 4-ferrocenylaniline was eluted with CH2Cl2. The CH2Cl2 
was removed using the rotary evaporator to obtain 4-ferrocenylaniline as a bright orange solid. 
Yield: 52 % (0.12 g). 1H NMR  = (CDCl3, 400 MHz, ppm): 7.22 (d, 2H, C6H4,), 6.56 (d, 2H, 
C6H4), 4.46 (s, 2H, C5H4), 3.96 (s, 5H,  C5H5), 3.55 (br, 2H, NH2).  
N-{[(Pyridin-2-yl)ethylidene]imino}phenylferrocene (L3) 
4- Ferrocenylaniline (0.04 g, 0.130 mmol) and 2-acetylpyridine  (0.13 g, 1.07 mmol) 
were put in a round bottom flask and anhydrous toluene (0.5 mL) was added and the mixture was 
heated at 120 C  for 5 hours. The solvent was then removed using the rotary evaporator under 
high vacuum. Yield: 42 % (0.06 g) C23H21N2Fe
+ ESI HRMS m/z: 381.2987, Calculated: 
381.10542, 1H NMR    = (CDCl3, 400 MHz ) 8.60 (dq 
1J = 4.84 Hz, 2J = 0.97 Hz, 1H Py-H6,), 
8.22 (dt, 1J = 8.10 Hz, 2J = 0.97 Hz, 1H, Py-H3 ), 7.72 (td, 1J = 7.89 Hz, 2J = 1.81 Hz,  1H, Py-
H4), 7.42 (d, 2H, C6H4), 7.29 (td, 
1J = 6.04 Hz, 2J = 1.17 Hz,  1H, Py-H5 ), 6.71 (d, 2H,  C6H4), 
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4.57 (t, 2H, C5H4),  4.24 (t, 2H, C5H4), 4.00 (s, 5H, C5H5), 2.34 (s, 1H, CH=N).  
(2-{[(Pyridinyl)methylidene]imino}phenyl)ferrocene (L4) 
4-Ferrocenylaniline (1.01 g, 3.45 mmol) and 2-pyridinecarboxaldehyde (0.880 g, 12.1 
mmol) were put into a round bottom flask and CH2Cl2 (1.00 mL) was added and the resulting 
solution was stirred at room temperature for 2 hours. The solvent was removed on the rotary 
evaporator. To remove any water by-product, the temperature of the rotary evaporator was 
increased to 60 C and the regulator set to maximum vacuum after 5 minutes until an orange 
brown solid mass was formed in the flask. Yield: 91 % (1.20 g) C22H19N2Fe
+ ESI HRMS m/z: 
367.0912, Calculated: 367.08977 1H NMR    = (CDCl3, 400 MHz, 8.65 (dq 
1J = 4.85 Hz, 2J = 
0.88, 1H Py-H6), 8.61 (s, 1H, CH=N), 8.15 (dt, 1J = 7.94, 2J = 0.95, 1H, Py-H3 ), 7.75 (td, 1J = 
7.76 Hz, 2J = 1.68 Hz,  1H, Py-H4 ), 7.45 (d, 2H, C6H4), 7.29 (td, 
1J = 6.18 Hz, 2J = 1.46 Hz,  1H, 
Py-H5), 7.21 (d, 2H,  C6H4), 4.59 (t, 2H, C5H4),  4.26 (t, 2H, C5H4), 3.99 (s, 5H, C5H5). 
Ferrocenoyl azide 
Caution: Azides are explosive, so to prevent any pressure build-up, an empty Vigreux 
condenser was attached to the reaction flask and protected with a blast shield in the fume hood. 
In a 100 mL round bottom flask, anhydrous CH2Cl2 (20 mL), ferrocenecarboxylic acid 
(2.00 g, 8.7 mmol), and oxalyl chloride (1.50 mL, 17.4 mmol) were added and cooled to 0 C. 
The reaction mixture was stirred vigorously and  a drop of dimethylformamide was added. The 
reaction was then allowed to warm to room temperature and stirred continuously for 3 hours. The 
reaction mixture was then concentrated under reduced pressure and the residue was taken up in 
anhydrous CH2Cl2 (20 mL) and cooled to 0 
oC. Tetra-n-butylammonium bromide (0.03 g, 0.09 
mmol) was then added followed by the addition of sodium azide (0.850 g, 13.1 mmol) in 
distilled water (4 mL). The reaction mixture was then allowed to warm to room temperature and 
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left to stir for 18 hours. The reaction was then quenched with distilled water (20 mL) and the 
organic layer was extracted twice with CH2Cl2. The combined organics were then dried over 
MgSO4 and concentrated under reduced pressure to yield the crude product. The product was 
then purified by silica gel column chromatography using (hexane 1:1 CH2Cl2) to give the 
compound as a crystalline orange solid. Yield: 85.8 %, (1.91 g). 1H NMR    = (CDCl3, 400 
MHz), 4.75 (t, 2H, C5H4),  4.44 (t, 2H, C5H4), 4.19 (s, 5H, C5H5). 
2-(Trimethylsilyl)ethyl ferrocenylcarbamate 
Anhydrous toluene (3 mL) was put  in a 25 mL 3-necked round bottom flask and 
ferrocenoyl azide (0.250 g, 1.00 mmol) was added. Trimethylsilyl ethanol (0.280 mL, 1.97 
mmol) was then added and the mixture was heated to reflux for 3 hours under nitrogen, resulting 
in a bright orange solution. After cooling to room temperature, the reaction mixture was 
transferred to a single necked round-bottom flask and concentrated under reduced pressure using 
the rotary evaporator to yield an orange solid mass of crude product. The product was purified by 
silica gel column chromatography using hexane and ethylacetate (EtOAc) (1:1) to give the 
product as a pale orange solid. Yield: 92 % (0.270 g). 1H NMR  = (CDCl3, 400 MHz) 8.63 (s, 
br, 1H, NH), 4.40 (s, 2H), 4.09-4.03 (7H, m), 3.86 (t, J = 1.85 Hz, 2H), 0.91 (t, 2H), 0.06 (s, 9H).          
Aminoferrocene       
2-(Trimethylsilyl)ethyl ferrocenecarbamate (0.60 g, 1.8 mmol) was added to a solution of 
tetrabutylammonium fluoride (TBAF) solution (1M) in THF (8 mL, 8 mmol) and the reaction 
mixture was heated to 50 °C for 2 hours. The reaction mixture was then allowed to cool to room 
temperature and concentrated under reduced pressure and the residue was quenched with water 
(20 mL), then extracted with CH2Cl2 (3 × 20 mL). The combined organics were dried over 
MgSO4 and concentrated under reduced pressure to yield the crude product. The product was 
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then purified by silica gel column chromatography using hexane and EtOAc (8:2). Yield: 50 % 
(0.20 g). 1H NMR δ = (400 MHz, CDCl3): 4.03 (s, 5H, C5H5), 3.92 (s, 2H, C5H4), 3.77 (s, 2H, 
C5H4), 2.5 (s, br, 2H, NH2). 
2-{[(Pyridinyl)ethylidene]iminoferrocene (L5) 
Aminoferrocene (0.10 g, 0.50 mmol) was dissolved  in 2-acetylpyridine  (0.06 g, 0.50 
mmol). To this solution was added anhydrous toluene (1 mL) and the compounds were heated to 
reflux for a period of 12 hours. The mixture turned into a brown solution and the solvent was 
removed on the rotary evaporator yielding a sticky brown product that was difficult to take out of 
the flask product. ESI HRMS m/z: 305.07 Calculated:  305.07, 1H NMR δ = (400 MHz, CDCl3): 
8.55 (d, 1H, Py-H6 ), 8.20 (d, 1H, Py-H3 ), 7.68 (td, 1J = 7.69, 2J = 1.61 1H, Py-H4), 7.23 (dd, 1J = 
4.85 Hz, 2J = 1.21 Hz, 1H, Py-H5 ), 4.45 (t, 2H, C5H4),  4.20 (t, 2H, C5H4), 4.00 (s, 5H, C5H5), 
2.45 (s, 3H, CH3).   
N-[(Pyridin-2-yl)methylidene]iminoferrocene (L6) 
2-Pyridinecarboxaldehyde (0.30 g,  2.77 mmol) and aminoferrocene (1.01 g, 2.77 mmol) 
were put in a round bottom flask. To this mixture, CH2Cl2 (0.50 ml) was added and the 
compounds were thoroughly stirred for a period of 12 minutes. The mixture turned into a red 
solution and the solvent was removed on the rotary evaporator to produce orange brown 
precipitate. Yield: 91.2% (1.23 g) product. Calculated: 291.09 ESI- HRMS m/z: 291.09, 1H 
NMR δ = (400 MHz, CDCl3): 8.68 (s, 1H, CH=N), 8.60 (dq, 
1J = 4.79 Hz, 2J = 0.94 Hz  1H, Py-
H6), 8.05 (d, 1H, Py-H3 ), 7.69 (td, 1J = 6.15 Hz, 2J = 1.65Hz,  1H, Py-H4 ), 7.26  (dd, 1J = 3.69 
Hz, 2J = 1.16 Hz, 1H, Py-H5 ), 4.61 ( t, 2H, C5H4),  4.26 ( t, 2H, C5H4), 4.12 (s, 5H, C5H5). 
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General UV-vis Experimental Conditions 
The stability of the compounds in 50% DMSO and aqueous phosphate buffered saline 
(PBS) at 37 oC and pH of 7.4 were determined using UV-vis spectroscopy over a period of 2 
hours. The spectra of the compounds were measured at a concentration of 100 µM. 
Results and Discussion              
Schiff base ligands L1 and L2 were synthesized according to already reported synthetic 
routes which involved the reaction of equimolar amounts of aniline with either 2-acetylpyridine 
or 2-pyridinecarboxaldehyde.37 For both L1 and L2 the reactions were carried out in toluene and 
at a temperature of 120 C to ensure that toluene boils to promote evaporation of any water 
formed from the condensation process. The synthetic scheme for compound L1 is shown in 
Figure 15.
 
Figure 15. Reaction scheme for Schiff base L1. 
 
In the 1H NMR spectrum, of L1 (Figure 16) the sixth hydrogen on the pyridine (Py) ring, 
Py-H6  appears as a doublet downfield  at chemical shift 8.59 ppm. The hydrogen at position 5 on 
the pyridine ring, and the two hydrogens labeled H8  on the benzene ring appear as overlapping 
28 
peaks at 7.30 ppm Py-H5. Next, a triplet at the chemical shift 7.71 ppm is assigned to the 
hydrogen on position 4, Py-H4 of the pyridine ring. Another doublet corresponding to the final 
hydrogen on position 3, Py-H3 of the pyridine ring, also appears at 8.20 ppm. Lastly, a multiplet 
at 7.07 ppm is assigned to the final hydrogen Ph-H9  of the conjugated aniline moiety. The three 
hydrogens on the methyl group bonded to the iminic carbon also appear upfield at 2.67 ppm as a 
singlet. The ESI-HRMS of the compound produced a molecular ion peak at m/z of 197.1079 
which was consistent with the calculated molecular mass. ESI-HRMS  spectrum of the 
compound is presented in APPENDIX A1.  
 
 
Figure 16. The 1H NMR Spectrum of Schiff base L1 in CDCl3 
 
L2 was also synthesized using equimolar amounts of 2-pyridinecarboxaldehyde using toluene as 
the solvent. Similar to L1 the reaction was also carried out at a temperature of 120 oC to ensure 
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effective reaction of the starting materials as well as avoid any possible decomposition by the 
formation of water by-product. The solvent was then removed to yield a brown liquid. The 
synthetic scheme of L2 is shown in Figure 17. 
  
Figure 17. Reaction scheme for Schiff base L2. 
 
Similar to L1,  the 1H NMR spectrum of L2 in Figure 17 also showed peaks spanning 
from  6.80 ppm to 8.20 ppm due to the four hydrogens on the pyridine ring and the three 
different hydrogen environments of the benzene ring . The major difference between the 
spectrum of L2 and L1 is the hydrogen (H10) on the iminic carbon showing as singlet at 8.15 




Figure 18. The 1H NMR spectrum of L2 in CDCl3 
 
The ESI-HRMS for L2 (APPENDIX A2)showed an intense molecular ion peak at m/z 
183.0922 which was consistent with the calculated mass-to-charge ratio of 183.0922. After 
successfully preparing the aniline Schiff base ligands, synthetic approaches were adopted to 
incorporate ferrocene into the ligands. The first example of this is L3 which involves  
the reaction between 2-acetylpyridine and 4-ferrocenylaniline. To synthesize 4-ferrocenylaniline, 
first, 4-nitrophenylferrocene was prepared by following an already prepared synthetic route  
using p-nitroaniline in a mixture of concentrated HCl, H2O, and aqueous NaNO2.
37 This mixture 
was added to a solution of hexadecyltrimethylammonium bromide (HDMBr) and ferrocene in 
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ether to make 4-nitrophenylferrocene. The reaction scheme is shown in Figure 19. 
 
Figure 19. Reaction scheme for the synthesis of 4-nitrophenylferrocene. 
 
In the 1H NMR spectrum of the compound, shown in APPENDIX A3, resonances were 
found to be consistent with those reported in literature. 31 The spectrum showed two doublets at 
8.16 ppm and 7.59 ppm  for the four hydrogens on the benzene ring. The three other peaks, a 
singlet corresponding to the unsubstituted aromatic ring was assigned a chemical shift of 4.03 
ppm. Finally, two triplets at 3.92 ppm and 3.76 ppm were assigned to the 4 hydrogen 
environments on the substituted cyclopentadienyl rings on the ferrocene.  
The prepared 4-nitrophenylferrocene was subsequently reduced by tin in ethanol and 
concentrated HCl to produce 4-ferrocenylaniline (Figure 20). Successful synthesis of the 
compound was confirmed by measuring the 1H NMR spectrum (APPENDIX A4). The spectrum 
appears similar to that of 4-nitrophenyl ferrocene with peaks at chemical shifts of 7.26 ppm and 
6.60 ppm due to the two different hydrogen environments on the benzene ring along with three 
peaks; two triplets at 4.46 ppm and 4.17 ppm due to the 4 hydrogens on the substituted aromatic 
ring of ferrocene and one  singlet of very high intensity assigned to the unsubstituted 
cyclopentadienyl ring also appears at 3.96 ppm. The spectrum also showed an additional broad 
peak of low intensity for the two hydrogens of the amine functional group which appeared at 





Figure 20. Reaction scheme for the synthesis of 4-ferrocenylaniline. 
 
Compound L3 was then synthesized by reacting an excess amount of two acetylpyridine 
with the prepared 4-ferrocenylaniline in anhydrous toluene. Following an analogous procedure to 
that of L1 and L2 the solution was heated to a temperature of 120 oC  (reflux) for 6 hours 
yielding a dark brown precipitate as product. The synthetic scheme of L3 is shown in Figure 22. 
 
 
Figure 21. Synthetic scheme of L3.  
 
L3 was characterized by 1H NMR spectroscopy and the spectrum is shown in Figure 23. 
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Figure 22. The 1H NMR spectrum of L3 in CDCl3.  
 
The spectrum of L3 showed the aromatic backbone spanning from the region 8.20 ppm to 
6.80 ppm owing to the pyridine as seen for L1 and L2. In addition to these peaks, two doublets 
were observed at chemical shifts 7.43 and 6.71 ppm due to the two different hydrogens H11 and 
H12 respectively on the phenyl group. Similar to the free ferrocenylaniline, the ferrocene group 
also showed three peaks; a singlet at 4.00 ppm, and two doublets appearing at  chemical shifts of 
4.25 ppm and 4.50 ppm. These observed peaks are shifted downfield relative to those of the free 
ferrocenylaniline, supporting the formation of the desired Schiff base. The hydrogens of the 
methyl group also showed up at 2.35 ppm whereas that of L1 appeared at 2.67 ppm. The ESI-
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HRMS (shown in APPENDIX A5) yielded a molecular ion peak of m/z 381.26 which was 
consistent with the calculated m/z of 381.26 confirming the successful synthesis. 
Schiff base ligand L4 was synthesized by reacting an equimolar amount of 4-
ferrocenylaniline and 2-pyridinecarboxaldehyde in dichloromethane and stirring for a period of 1 
hour. The reaction scheme of L4 is shown in Figure 23. 
 
 
Figure. 23 Synthetic scheme of L4. 
 
The 1H NMR spectrum (Figure 25) of L4 is similar to L3 showing 4 peaks in the region 
of 8.85 ppm to 7.45 ppm and additional two peaks at 7.29 ppm and 7.21 ppm due to the two 
hydrogen H11 and H12 environments of the benzene ring. Compared to L3, the methyl group at 
2.7 ppm of L3 is replaced by a singlet H16 on L4 downfield at chemical shift 8.60 ppm. 
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Figure 24. The 1H NMR spectrum of L4 in CDCl3 
 
To confirm a successful synthesis, ESI-HRMS (APPENDIX A6) of L4  was performed. 
An intense molecular ion peak at m/z 367.09 was observed which was consistent with the 
calculated mass-to-charge ratio of 367.09.  
After successfully synthesizing the Schiff base ligands using aniline and modifying the 
compounds to include ferrocene, compounds L5 and L6 were synthesized by reacting 2-
acetylpyridine and 2-pyridinecarboxaldehyde respectively with aminoferrocene. Since 
aminoferrocene is very expensive we took a synthetic approach that was comprised of three steps 
starting with ferrocencarboxylic acid. In the first step, ferrocenoyl azide was prepared by 
reacting ferrocencarboxylic acid with oxalyl chloride dimethylformamide (DMF) and sodium 
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azide in dichloromethane. The product was confirmed by measuring the 1H NMR spectrum 
(APPENDIX 7). Three peaks were observed; two triplets at chemical shifts of 4.75 ppm and 4.44 
ppm were assigned to the four hydrogen on the substituted cyclopentadienyl ring and a singlet at 
4.19 ppm chemical shift were assigned to the five hydrogens  on the unsubstituted 
cyclopentadienyl ring. The resonances observed were consistent with the spectrum reported in 
literature indicating a successful synthesis of the compound. 40 The synthetic scheme of the 
compound is shown in Figure 25. 
 
Figure 25. Synthetic scheme of ferrocenoyl azide from ferrocenecarboxylic acid. 
 
Since azides are unstable compounds, a protecting group, 2-(trimethylsilyl)ethanol, was 
added to form 2-(trimethylsilyl)ethyl ferrocenylcarbamate as shown in Figure 26.  
 
Figure 26. Synthetic scheme to prepare 2-(trimethylsilyl)ethylferrocenylcarbamate from 
ferrocenoyl azide. 
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The 1H NMR spectrum (APPENDIX A8) of the 2-
(trimethylsilyl)ethylferrocenylcarbamate showed 5 peaks spanning the entire spectra window. 
Beginning downfield, the peak at a chemical shift of 8.63 ppm was assigned to the hydrogen on 
the carbamate functional group. Next, two doublets at 4.40 and  4.09 ppm correspond to the 
substituted arene ring on the ferrocene, while the singlet at 3.86 ppm was assigned to the 
unsubstituted ring. Lastly, upfield, a singlet at 0.06 ppm was assigned  to the 9 hydrogens on the 
trimethylsilyl (TMS) group. These resonances were consistent with that of the compound already 
reported in literature.40 The carbamate compound is stable and can undergo further reaction 
without decomposition. 
The final step in the synthesis used tetrabutylammonium fluoride (TBAF) in 
tetrahydrofuran (THF) to deprotect the carbamate to yield the target aminoferrocene. This was 
achieved by refluxing the reaction mixture in THF for a period of 2 hours. The 1H NMR 
(APPENDIX A9) of aminoferrocene was measured and resonances were observed at the 
ferrocenyl region. Compared to the carbamate compound, the hydrogens on the unsubstituted 
cyclopentadienyl was shifted downfield to 4.03 ppm whereas the four hydrogens on the 
substituted arene ring appeared at 3.92 ppm and  3.77 ppm. Additionally,  a broad short peak at 
2.50 ppm due to the 2 hydrogens on amine functional group was also observed in the spectrum. 
The spectrum was consistent with that as reported in literature.40 The reaction scheme of 





Figure 27. Synthetic scheme to prepare aminoferrocene from 2-
(trimethylsilyl)ethylferrocenylcarbamate. 
Having successfully prepared aminoferrocene, compound L5 was then synthesized by 
refluxing equimolar amounts of aminoferrocene and 2-acetylpyridine in anhydrous toluene for 2 
hours. The synthetic scheme of the reaction is represented in Figure 28. 
 
 
Figure 28. Synthetic scheme to prepare L5. 
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The 1H NMR spectrum (Figure 29) of the compound showed resonances within the 
aromatic region due to the pyridine ring which spans the region of 8.55 ppm to 7.25 ppm similar 
to compound L1. However, the multiplet observed at chemical 7.03 ppm assigned to the 
conjugated benzene ring in compound L1 is replaced by two doublets at chemical shifts 4.25 
ppm and 4.45 ppm due to the substituted aromatic ring of ferrocene and a singlet of high 
intensity at 4.00 ppm assigned to the unsubstituted ring. These chemical shifts of the ferrocene 
backbone are consistent with those of compounds L3 and L4. Similar to  compounds L1 and L3 
where the hydrogens on the methyl group appears as a singlet at chemical shifts 2.35 ppm and 
2.65 ppm respectively, the hydrogens on the methyl group (H18) of L5 also appeared as a singlet 
at 2.40 ppm. The molecular ion peak  (APPENDIX A10) m/z 305.07 did not vary with that 
calculated confirming a successful synthesis of the Schiff base compound. 
       
Figure 29. The 1H NMR spectrum of Schiff base L5 in CDCl3. 
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Similar to compound L4, L6  was synthesized by stirring a mixture aminoferrocene and 
2-pyridinecarboxaldehyde dichloromethane at room temperature for 1 hour (Figure 31). After 
mixing the solvent was removed completely to yield a dark violet precipitate. 
 
Figure 30. Synthetic scheme of L6. 
 
The 1H NMR spectrum of L6  is similar to L5. The major difference, similar to the 
previous Schiff base, lies in the resonances due to the methyl of 2-acetylpyridine and the 
hydrogen of the 2-pyridinecarboxaldehyde. The methyl group which appears at a chemical shift 
of 2.40 ppm is replaced by the hydrogen, H17 which appears at 8.68 ppm. ESI-HRMS 
(APPENDIX A11) data yielded a molecular ion peak of m/z 291.06 which matches that obtained 
from the calculated mass-to-charge ratio of 291.05 for L6.  
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Figure 31. 1H NMR spectrum of L6. 
To check the stability of the Schiff base ligands in aqueous PBS and 50% DMSO at 37 
oC for 2 hours, the UV-vis spectra of  the six Schiff bases were collected. The spectrum of L1 is 
shown in Figure 32 and those of L3, L5, and L6 are shown in APPENDIX A12. 
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Figure 32. UV-vis spectrum of L1 in 50% DMSO and PBS(aq) at pH of 7.4 and a temperature 
of 37 oC. 
 
The UV-vis spectrum of L1 did not vary over a period of 2 hours. Similarly, the spectra 
collected for  L3, L5, and L6 also did not change over the same period of measurement. This 
suggests that these ligands are stable under the given set of conditions. However, the UV-vis 
spectrum of compounds L2 and L4 continuously varied over the same 2-hour measurement  



















Figure 33. UV-vis spectrum of L2 in 50% DMSO and PBS(aq) at pH of 7.4 and a temperature 
of 37 oC. 
 
The spectrum of L4 (Figure 35) also showed variation in absorbance over the 2-hour 
period. The spectrum showed an isosbestic point at a wavelength of 290 nm where the 
absorbance of the compound remained constant. This indicates the formation of a new compound 
directly from the complex in the buffer solution. 1H NMR spectrum of the ligand L2 under the 




















Figure 34. UV-vis spectrum of L4 in 50% DMSO and PBS(aq) at pH of 7.4 and a temperature 
of 37 oC. 
Conclusion 
Six Schiff base ligands were successfully synthesized by reaction of each of 2-
acetylpyridine and  2-pyridinecarboxaldehyde with aniline, 4-ferrocenylaniline and 
aminoferrocene. The Schiff bases were characterized using 1H NMR and ESI-HRMS and their 
aqueous stability was assessed using UV-vis Spectroscopy. These compounds were subsequently 
























CHAPTER III: SYNTHESES OF RUTHENIUM(II) ARENE COMPLEXES 
 CONTAINING SCHIFF BASE LIGANDS 
Ruthenium(II) Arene Schiff Base (RAS) Complexes  
Due to the pharmaceutical significance of Schiff bases, recent design of Ru(II) anticancer 
compounds take into consideration the use of Schiff bases to improve the efficacy of the 
compounds. Chow et al.  evaluated the anticancer activity of three Ru(II) arene Schiff base 
compounds (Figure 35).42 In this study, cisplatin was found to be inactive against MCF breast 
cancer cell with IC50 greater than 50 µM. However, all the three compounds a, b, and c  were 
found to be more active with IC50 values of 2.93 µM, 6.47 µM and 13.17 µM respectively.  
 
  
Figure 35. Examples of ruthenium(II) Schiff base complexes.          
 
The Schiff base ligands L1 to L6 were then reacted with the Ru(II) dimer starting 
material  to produce new Ru(II) anticancer compounds (Figure 36).  
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Figure 36. Ruthenium(II) arene Schiff base target compounds. 
Experimental 
General Materials and Methods  
The reagents utilized were purchased from Fisher Scientific, Sigma Aldrich, Cambridge 
Isotope Laboratories, or Oakwood Chemical. All chemicals acquired were used as received. The 
1H NMR of the complexes were all measured with 16 scans, and field centered at 6 ppm, a sweep 
width of 20 ppm, and a relaxation time of 1 second. Elemental Analysis (EA) data were collected 
by the University of Illinois Urbana-Champaign School of Chemical Sciences Microanalysis 
Laboratory where acceptable values are within ±0.4 weight % of the theoretical values for each 
element (C, H, N).  
Instrumentation 
 The 1H NMR spectrum of the ruthenium(II) arene Schiff base compounds were collected 
using a Bruker Avance III 400 MHz NMR spectrometer with either CDCl3 or DMSO- d6 as the 
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solvent. The 1H NMR spectra of the compounds were processed using the Topspin 2.1 software. 
The UV-vis spectra of the Ru(II)  complexes were collected using an Evolution 260 Bio 
Spectrophotometer equipped with a single cell Peltier system and a Haake DC 10 pump. The 
software on which the experiments were run was the Thermo INSIGHT software. 
Synthesis of Ru(II) starting material 
RuCl3·3H2O (1.01 g, 4.90 mmol) was dissolved in ethanol (50 mL) and 𝛼-phellandrene 
(10 mL, 30.52 mmol) was added. The mixture was heated at reflux for 4 hours and then cooled 
to room temperature. The solvent was evaporated to half volume and the mixture kept in the 
freezer overnight and filtered to produce an orange brown solid. Yield: 75 % (1.035 g) 1H NMR 
δ = (400 MHz: 5.95 (d, 2H, J = 6.79 Hz) 5.83 (d, 2H, J = 5.86 Hz), 5.60 (d, 2H, J = 5.94 Hz), 
2.85 (sep, 2H, J = 6.54 Hz), 2.22 (s, 3H), 2.18 (s, 3H), 1.31 (t, 12H, J = 7.09 Hz). 
Synthesis of Compound C1 
The prepared Ru(II) arene dimer (0.22 g, 0.37 mmol) and Schiff base ligand L1 (0.15 g, 
0.75 mmol) were put into a 25 mL round bottom flask. High performance liquid chromatography 
(HPLC) grade methanol (8 mL) was then added. The reaction was then stirred at room 
temperature for 4 hours. Ammonium hexafluorophosphate (0.29 g, 1.87 mmol) was then added 
directly and the resulting mixture was stirred for 10 minutes, then the reaction mixture was kept 
in the fridge (4 oC) overnight and solid precipitates were formed. The product was then filtered 
off and dried to yield the product as a bright orange solid. Yield: 53 % (0.060 g) 1H NMR δ = 
(400 MHz, CDCl3):  9.35 (d, 1H, J = 5.67 Hz, Py-H
6), 8.12 (td, 1H, 1J = 6.46, 2J = 1.58 Py-H5), 
8.04 (d, 1H, J = 7.89 Hz, Py-H3), 7.76 (dd, 1H, 1J = 4.12, 2J = 1.41, Py-H4) 7.48 (t, 1H,  Ph-H8), 
5.50 (t, H, Ph- H7), 5.48 (d, 2H, p-Cym- H12), 5.27 (dd, 2H, J = 6.14 Hz, p-Cym- H13), 2.7 (sep, 
1H, J = 7.09, CH(CH3)2), 2.50 (s, 3H, p-Cym-CH3), 2.12 (s, 3H, CH3 C=N), 1.12 (d, 3H, J = 6.82 
CH(CH3), 1.03 (d. 3H, J = 6.99 CH(CH3).  
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Synthesis of Compound C2 
 The prepared Ru(II) arene dimer (0.22 g, 0.36 mmol) and Schiff base ligand L2 (0.13 g, 
0.72 mmol)  were put into a 25 mL round bottom flask. HPLC grade methanol (8 mL) was then 
added. The reaction was then stirred at room temperature for 4 hours. Ammonium 
hexafluorophosphate (0.29 g, 1.80 mmol) was then added directly and the resulting mixture was 
stirred for 10 minutes, then the reaction mixture was kept in the fridge overnight and solid 
precipitates were formed. The product was then filtered off and dried to yield the product as a 
dark purple solid. Yield: 83 % (0.18 g) 1H NMR δ = (400 MHz, CDCl3): 9.34 (d, 1H, J = 6.19 
Hz, Py-H6), 8.44 (s, 1H, CH=N), 8.10 (t, 1H, J = 6.24 Py-H5), 7.83 (d, 1H, J = 7.08 Hz, Py-H3), 
7.76 (dd, 7.58 (m, 1H,  Ph-H7,8,9), 5.74 (d, 2H, Ph- H7), 5.48 (d, 2H, p-Cym- H12), 5.43 (dd, 2H, 
p-Cym- H13), 2.7 (sep, 1H, J = 6.90, CH(CH3)2), 2.19 (s, 3H, p-Cym-CH3), 1.21 (d, 3H, J = 6.90 
CH3), 1.16 (d. 3H, J = 6.90 CH3). Elemental Analysis (C, H, N, weight % C22H24RuPF6Cl∙H2O): 
Theoretical: 42.9 % C, 4.25 % H, 4.55 %N. Experimental: 43.12 % C, 3.89 % H, 4.69 % N.  
Synthesis of Compound C3 
The prepared Ru(II) arene dimer (0.0800 g, 1.33 mmol)  and Schiff base ligand L3 (0.100 
g, 0.262 mmol) were put into a 25 mL round bottom flask. HPLC grade methanol (8 mL) was 
then added. The reaction was then stirred at room temperature for 4 hours. Ammonium 
hexafluorophosphate (2.12 g, 13.3 mmol) was then added directly and the resulting mixture was 
stirred for 10 minutes, then the reaction mixture was kept in the fridge (4 oC) overnight and solid 
precipitates were formed. 1H NMR spectrum of the compound showed several peaks in the 
aromatic region and in the ferrocenyl region. Reaction appeared unsuccessful will be carried out 
again in the future . 
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Synthesis of Compound C4 
The prepared Ru(II) arene dimer (0.13 g, 0.20 mmol) and Schiff base ligand  L4 (0.12 g, 
0.41 mmol) were put into a 25 mL round bottom flask. HPLC grade methanol (8 mL) was then 
added. The reaction was then stirred at room temperature for 4 hours. Ammonium 
hexafluorophosphate  (0.170 g, 1.02 mmol) was then added directly and the resulting mixture 
was stirred for 10 minutes, then the reaction mixture was kept in the fridge overnight and solid 
precipitates were formed. The product was then filtered off and dried to yield the product as a 
dark purple. solid. Yield: 53 % (0.17 g) 1H NMR δ = (400 MHz, CDCl3): 9.30 (s, 1H, CH=N), 
8.22 (d, 1H, J = 7.73 Hz, Py-H6), 8.05 (t, 1H, J = 7.73 Hz, Py-H5), 7.70 (t, J = 6.24 Hz Py-H4), 
5.88 (d, J = 6.30 Hz,  1H,  Ph-H3), 5.49 (t, J = 5.67Hz, 2H, p-Cym-H12), 5.37 (d, J = 5.67 Hz, 2H, 
p-Cym- H13), 5.43 4.84 (s, 2H, ), 4.55 (d, J = 13.53, 2H), 4.29 (s, 5H)   2.61 (sep, 1H, J = 7.00, 
CH(CH3)2), 2.24 (s, 3H, p-Cym-CH3), 1.13 (d, 3H, J = 6.53 CH3), 1.07 (d. 3H, J = 6.53 CH3). 
Synthesis of  Compound C5 
The prepared Ru(II) arene dimer (0.100 g, 0.16 mmol)  and Schiff base ligand L5 (0.0450 
g, 0.147 mmol) were put into a 25 mL round bottom flask. HPLC grade methanol (8 mL) was 
then added. The reaction was then stirred at room temperature for 4 hours. Ammonium 
hexafluorophosphate (2.12 g, 13.3 mmol) was then added directly and the resulting mixture was 
stirred for 10 minutes, then the reaction mixture was kept in the fridge (4 oC) overnight and solid 
precipitates were formed. 1H NMR spectrum of the compound showed several peaks in the 
aromatic region making assignments difficult. Reaction condition will be varied and carried out 
again in future.  
Synthesis of  Compound C6 
The prepared Ru(II) arene dimer (0.110 g, 0.180 mmol)  and Schiff base ligand L6 (0.110 
g, 0.360 mmol) were put into a 25 mL round bottom flask. HPLC grade methanol (8 mL) was 
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then added. The reaction was then stirred at room temperature for 4 hours. Ammonium 
hexafluorophosphate (0.110 g, 0.710 mmol) was then added directly and the resulting mixture 
was stirred for 10 minutes, then the reaction mixture was kept in the fridge overnight and solid 
precipitates were formed. The product was then filtered off and dried to yield the product as a 
dark green solid. Yield: 72 % (0.20 g) 1H NMR δ = (400 MHz, CDCl3): 9.31 (d, 1H, J = 5.52 Hz, 
Py-H6), 8.48 (s, 1H, CH=N),  8.1 (t, 1H, J = 5.58 Hz, Py-H5), 7.75 (t, J = 8.49 Hz Py-H4), 7.64 
(d, J = 8.56 Hz,  1H,  Ph-H3), 5.76 (d, J = 5.67 Hz, 2H, p-Cym-H12), 5.52 (d, J = 6.32 Hz, 2H, p-
Cym- H13), 5.45 (d, J = 6.10 Hz, 2H)  4.78 (s, 2H, Cp), 4.49 (s, 2H, Cp), 4.12 (s, 5H, Cp),  2.76 
(sep, 1H, J = 6.94, CH(CH3)2), 2.21 (s, 3H, p-Cym-CH3), 1.22 (d, 3H, J = 6.95 CH3), 1.17 (d. 
3H, J = 6.95 CH3). 
General UV-vis Spectra Conditions 
The UV-vis spectra of the compounds were measured using a solution of the complexes 
at a concentration of 100 µM in 10 % DMSO and aqueous PBS (pH 7.4). The samples were 
incubated at 37 oC and spectra were collected every 30 minutes over a period of 6 hours. 
Results and Discussion 
The ruthenium dimer starting material  was synthesized by reaction of RuCl3·3H2O with 
an excess of 𝛼-phellandrene and heated to (reflux) for four hours. The reaction mixture was then 
concentrated on the rotary evaporator and stored in the fridge overnight. The product was then 




Figure 37. Reaction scheme for the synthesis of  Ru(II) arene dimer starting material. 
 
 
Figure 38. The 1H NMR spectrum of the Ru(II) arene dimer in D2O. 
 
The compound was characterized by collecting the 1H NMR spectrum, shown in Figure 
38.  The hydrogens (H18) on the two methyl groups directly bonded to the benzene ring appear 
upfield in the spectrum as two singlets at chemical shifts 2.22 pm and 2.18 ppm. The four unique 
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hydrogens, H19- H22, on the asymmetrical benzene rings appear in the spectrum as four doublets 
spanning the region of 5.25 ppm to 6.95 ppm.  Another major diagnostic peak is that of the 
hydrogen (H1)  which appears in the spectrum as a septet at the chemical shift 2.85 ppm. The 
twelve hydrogens from the four methyl groups  also appears as two doublets at chemical shifts of 
1.31 ppm. These reported chemical shifts match those reported in literature for the Ru(II) dimer. 
The Ru(II) complexes were then synthesized by reacting the Ru(II) dimer species with the 
respective six Schiff base ligands from chapter two. 
All four compounds C1, C2, C4 and C6 were synthesized according to one general 
procedure (Figure 39). The  ruthenium dimer and the respective Schiff base ligand were 
dissolved in HPLC grade methanol, and the reaction mixture was allowed to stir at room 
temperature for 4 hours. This was to ensure a complete reaction between the Ru compound and 
the Schiff base ligand. Ammonium hexafluorophosphate (5 equivalents) was then added to the 
mixture and stirred for 10 minutes. The phosphate was added to the mixture to aid the 
precipitation of the product. A previous synthetic attempt used tetrabutylammonium 
hexafluorophosphate (Bu4NPF6), where the 
1H NMR spectra of the isolated compound showed 
significant precipitation of the Bu4NPF6  salt as opposed to the desired product. Hence, the 







Figure 39. General reaction scheme for the Ru(II) arene Schiff base compounds. 
 
 
Figure 40. The 1H NMR spectrum of complex C1 in CDCl3. 
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In the 1H NMR spectrum (Figure 40) of complex C1, the Py-H6 and Py-H3 appear as 
doublets at 9.4 ppm and 8.05 ppm respectively. In the aromatic region, Py-H4 appears as a triplet 
at 7.80 ppm whereas H5 also appears as another triplet at 8.15 ppm. Additionally, the hydrogens 
H7, H8,  and H9 on the benzene ring also appear as a multiplet at 7.50 ppm. Compared to the 
hydrogens on ligand  L1, these hydrogens on C1 are shifted further downfield to higher chemical 
shifts. This may be due to deshielding of the hydrogens as a result of the +2 oxidation state of the 
Ru ion which strongly pulls away electrons from the hydrogens. Two other triplets in the 
aromatic region are also observed at 5.55 ppm and 5.35 ppm due to the two different hydrogen 
environments, H19 and H20 respectively on the ring in the cymene group. Another  major 
diagnostic peak for the synthesis of this complex is the appearance of the septet at 2.75 ppm due 
to the hydrogen labelled H1 that is para to the methyl group on the cymene ring. These three 
different hydrogen environments on the cymene ring appear shifted upfield relative to the 
hydrogens on the Ru(II) dimer starting material.  Another group of hydrogens are those of the 
methyl group directly bonded to the cymene ring, H18 which  appears as a singlet at 2.50 ppm. 
Another singlet due to the three hydrogens on the methyl group H10, bonded to the iminic carbon  
is also shifted upfield  in the spectrum to 2.22 ppm compared to 2.67 ppm on the ligand L1. 
Similar to the observations made for the hydrogens on the cymene ring, the  six hydrogens of the 
isopropyl group on the cymene are also shifted further upfield to 1.12 ppm and 1.03 ppm from 
2.18 and 1.31 respectively in the Ru-dimer. Overall, the resonances observed matches similar 
compounds that have been reported in literature confirming a successful synthesis of the 
compound 
Having successfully synthesized C1, the same general procedure was used to synthesize 
complex C2. The compound was characterized by collecting the 1H NMR spectrum in Figure 41 
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Figure 41. The 1H NMR spectrum of complex  C2 in CDCl3. 
 
The 1H NMR spectrum of C2 is similar to L2 . The four hydrogens on the pyridine as well 
as the three different hydrogens of the benzene ring appear  in the spectrum spanning the region 
of 9.34 ppm to 7.6 ppm as observed in compound C1. The major difference between the 
spectrum of C1 and C2 is the replacement of the methyl group of C1 by a hydrogen, H10 which 
appears downfield at 8.44 ppm. Comparing these chemical shifts of C2 to the Schiff base ligand 
L2, a similar observation made for compound C1 was seen where all the hydrogens on the 
pyridine and benzene rings were shifted further downfield to higher chemical shifts relative to 
the free Schiff base. Finally, as observed in complex  C1 the six different hydrogens of the 
cymene were all shifted upfield relative to the Ru(II) dimer staring material. Results of the 
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elemental analysis of the composition of carbon, hydrogen and, nitrogen and was consistent with 
the calculated percentages confirming a successful synthesis of C1 and by extension C2 as well 
Another synthesis was carried out following the synthetic procedure used to synthesize 
compound C1 and C2  to make C3. However, the reaction did not appear to work, as the NMR 
showed several complex peaks within the aromatic region in the spectrum. The reaction 
conditions are being modified to achieve a better results. 
Another Ru(II) arene Schiff base compound, C4 was synthesized by reacting the Ru dimer with 
L4 and characterized by collecting the 1H NMR spectrum (Figure 42). 
 
Figure 42. The 1H NMR spectrum of complex C4 in CDCl3. 
                                                                                                                                                      
 The 1H NMR spectrum  of C4 appears similar to complex C2. As expected,  the 1H NMR 
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spectrum  resonances show spanning the spectrum from  9.3 ppm to 7.6 ppm due to the pyridine 
and phenyl rings . However, unlike C2 the structure of the compound is modified to include 
ferrocene which introduces three new peaks into the spectrum. First, two singlets due to H14 and 
H15 on the substituted aromatic ring of ferrocene is seen in the region of 4.8 ppm and 4.5 ppm. 
The five hydrogens of the unsubstituted aromatic H13, also show up as an intense singlet peak at 
chemical shift 4.1 ppm. Relative to the Schiff base ligand L4  the ferrocene peaks appear shifted 
slightly downfield. As  a general trend so far, all the hydrogen environments of the cymene shift 
upfield after bonding to the Ru(II) metal.  
The fifth synthetic attempt was C5 using the same procedure as before. However, the 
reaction did not work as the NMR showed several peaks spanning the region 5.5 ppm to 8.5 ppm 
in the peaks in the spectrum. The reaction conditions are being changed to possibly make this 
compound. 
The last successful compound synthesized was the Ru(II) compound C6 using the same 
procedure as described earlier and characterized by collecting the 1H NMR spectrum. The 1H 
NMR spectrum of compound C6 (Figure 43) was used to confirm the synthesis of the compound. 
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Figure 43. The 1H NMR spectrum of complex C6 in CDCl3. 
 
The complex C6 shows 1H NMR spectrum similar to complex C4.  However, the 
hydrogen, H18  of the imine appears at 9.30 ppm. Resonances of two doublets and two triplets for 
the four hydrogen environments on the pyridine ring span the spectrum from 9.30 ppm to 5.70 
ppm. The spectrum shows a singlet at 4.85 ppm and  doublet at 4.55 ppm due to the hydrogens 
H14 and H15 on the substituted cyclopentadienyl ring of ferrocene. Another intense singlet peak at 
4.25 ppm was assigned to the five hydrogens, H13 of the unsubstituted cyclopentadienyl ring. 
This range of chemical shifts agrees with the ferrocenyl peaks of C4 and those of Schiff base L6, 
however, as seen in C4,  the ferrocene peaks assigned to C6 are shifted slightly downfield relative 
to L6. The major difference between C4 and C6 are the two doublets from the four hydrogens due 




shifts 5.45 ppm and 5.55 ppm in C4 but are absent in C6. The observed NMR signals suggest a 
successful synthesis bringing the total number of Ru Schiff base complexes prepared to 4 
UV-vis experiments                                                                                       
An important step in the mechanism of action of anticancer drugs is their ligand exchange 
behavior. Therefore, the stability of the four successfully synthesized ruthenium arene complexes 
C1, C2, C4, and C6 were all studied in 10 % DMSO and  aqueous PBS at a pH of 7.4 and a 
temperature of 37 oC. The UV-vis spectrum of each compound was collected every 30 minutes 
for a period of 6 hours using a concentration of 100 µM. Over the six-hour period, the measured 
spectra for all of the compounds did not vary. The spectrum of the compound compound C1 is 
shown in Figure 45 while the spectra for the remaining compounds can be found in .  
Studies have shown that  the presence of the arene group at three coordinate site of the 
Ru(II) ion alters the electron distribution of the compound and stabilizes the Ru(II) the 
compound towards ligand exchange.43 This behavior of compounds C1, C2, C4, and C6 in 
aqueous PBS  are consistent with the earlier reported observations on Ru(II) arene compounds.  
It was therefore proposed that the four compounds are stable under physiological conditions of 
37 oC and pH of 7.4. Comparing the UV-vis spectrum of ligand L2 and L4 to their respective 




Figure 44. UV-vis spectrum of 100 µM solution of C1 in 10% DMSO and PBS(aq) at a pH of 





In all, four Ru(II) compounds, C1, C2, C4 and C6, have been synthesized according to one 
general procedure. The compounds have so far been characterized by 1H NMR spectroscopy. In 
addition, compound C2 has been confirmed by elemental analysis. Efforts were made to 
synthesize the remaining compounds C3 and C5, but the resulting NMR spectra were difficult to 
interpret. By varying the mole ratios of the reaction and carrying out the reaction for a longer 
duration, it is hoped that the complexes will be prepared. The stability of the 4 prepared 
compounds in aqueous buffer was also evaluated and all four complexes have so far proved very 




















CHAPTER IV: PRELIMINARY STUDIES ON THE INTERACTION  
BETWEEN THE RUTHENIUM(II) ARENE COMPLEXES  
AND HUMAN SERUM ALBUMEN 
Introduction 
 Protein binding is an important consideration in the mechanism of action of any 
pharmaceutical. It is believed that most ligands present in human blood bind to plasma proteins, 
and, to a varying extent, these bindings are reversible.59 Protein binding facilitates drug solubility 
in human plasma, enhancing its delivery to the target tissue, which is important in the case of 
low-soluble, hydrophobic chemicals. Drug binding with the human serum albumin (HSA) 
protein minimizes its toxicity and may potentially increase the in vivo half-life of a therapeutic 
agent.59  
Ru(II) compounds bind to metal-transporting proteins from human blood such as human 
serum albumin (HSA) and serum transferrin (Tf). However, the binding affinity of ruthenium 
compounds to these two proteins revealed that HSA bind  more favorably than transferrin.3, 61 
Transferrin is a blood plasma protein  that transports iron into the cells by binding to the 
transferrin-receptor (TfR) on the cell membrane.62 HSA is the most abundant protein in plasma 
and makes up approximately half of the protein found in human blood with a concentration of 
about 5 g / 100 mL.63, 64, 66 This protein (Figure 46) is comprised of 585 amino acids in a single 
polypeptide chain, with three R-helical domains (I-III).  Each helical domain has two 
subdomains A and B.  The protein contains 17 disulfide bridges which stabilizes the helical 
structure.63,64, 65 The disulfide bridges make the helical, globular structure rigid, but provide 




Figure 45. Crystal structure of HSA showing the domain-binding sites (Sudlow I and Sudlow II).67   
 
Studies by Sudlow et al. in the 1970s revealed two drug binding sites on HSA. These 
principal regions of drug binding sites in albumin are found in hydrophobic cavities in subdomains 
IIA and IIIA. These binding sites are called Sudlow I and Sudlow II, respectively and the 
tryptophan residue in HSA is located in Sudlow I (Trp-214).67  Almost the entire fluorescence of 
HSA is produced by the tryptophan residue. Albumin principally functions as a carrier protein 
which binds and transports fatty acids, hormones, metabolites, and drugs.64,65,66 The binding 
affinity of a molecule to HSA, therefore regulates the distribution and metabolism of drugs which 
necessitates HSA-ligand interaction studies since strong binding may reduce bioavailability and/or 
increase the drug’s in vivo half-life.66, 67 
Fluorescence spectroscopy is a common technique that is employed to investigate the interaction 
between a drug and HSA. The technique enables the tryptophan residue from which the 
fluorescence was obtained to be verified and hence determine the number of sites and binding 
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constant, Kb of the interaction between the protein and the drug.  It is also possible to identify the 
type of binding that occurs between the HSA protein and the drug and the mechanism by which 
the binding occurs. 
The four synthesized Ru(II) arene Schiff base compounds, were evaluated for their 
interaction with HSA. This investigation is necessary to establish  whether the compounds could 
potentially target proteins, which will impact the bioavailability and distribution of the compounds.  
Experimental 
General Materials and Methods  
Human serum albumin was acquired from Sigma Aldrich as a lyophilized powder and used 
as received.  The remaining chemicals used were purchased from Fisher Scientific, Sigma Aldrich, 
or Oakwood Chemical. All chemicals acquired were used as received. The synthesized compounds 
were also used as they were prepared as described in chapter 3. 
Instrumentation 
The fluorescence spectrometer used was a VARIOSKAN LUX from Thermo Fisher 
equipped with SkanIt software. The experiments were run in F-brand Flat bottom 96-well plates. 
The incubator used was a Fisher brand IsoTemp. The fluorescence data obtained were processed 
in Excel. 
General Fluorescence Experimental Conditions 
A stock solution of HSA (0.110 mM, 5.00 mL) was prepared using aqueous PBS at a pH 
of 7.4 and stored in the fridge. Then 50 µM solution of each of the Ru(II) complexes were also 
prepared in 10% DMSO  and aqueous PBS. After preparing the samples, 47.5 µL of the stock 
solution of  HSA was placed in 11 different vials. To the first vial, 30 µL of the prepared 
complex solution was added. To the second up to the tenth vial the complex solutions were 
added in increasing amounts of 30 µL of the previous amount. Aqueous PBS was then added to 
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make a final volume of 600 µL. The stock solutions HSA- complex were incubated for a period 
of 1 hour at a temperature of 37 oC and then  each was transferred as triplicates into a 96-well 
plates. The excitation wavelength was set at 280 nm and the emission spectra were collected at 
299 nm to 600 nm. Another batch of the measurements were also carried out following the same 
procedure but incubated at 25 oC. 
Results and Discussion  
Fluorescence quenching, a widely used technique for studying the binding affinities 
between HSA and organic or inorganic complexes was employed to investigate the interaction of 
complexes C1, C2, C4 and C6 with HSA. The technique shows a decrease in the quantum yield of 
fluorescence from a fluorophore induced by  molecular interactions with a quencher molecule. 
Albumin proteins have intrinsic fluorescence due to the presence of three fluorophores: 
tryptophan, tyrosine and phenylalanine. Phenylalanine and tyrosine are reported to contribute to 
fluorescence quenching  by a small amount. Almost the entire fluorescence observed from HSA 
is produced from the tryptophan residue in Sudlow I.62 The fluorescence intensity detected as a 
function of the concentration of complex C2 by exciting HSA at 280 nm and collecting its 
emission spectrum from 299 nm to 600 nm is shown in Figure 46. The spectra yielded a λ max 
of 306 nm. 
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Figure 46. Fluorescence spectra of HSA (2.5 μM) in the presence of increasing concentration of 
C2 from 0 μM up to 25 µM at 37 oC and pH of 7.4.  
  
As  the concentration of the complex increases, the HSA fluorescence intensity decreases. 
The quenching process occurring may be either static or dynamic. Dynamic quenching occurs 
when the interaction between the quencher and the excited state of the fluorophore occurs 
through collisions during the life-time of the fluorophore excited state. If the quenching process 
is static, the interaction between the fluorophore and quencher occurs in the ground state, with 
formation of a new species which is not luminescent.62 
The Stern–Volmer equation is commonly used to determine the type of quenching 
mechanism by analyzing the relation: 
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 Fo/F = Ksv[Q] + 1= 𝜏𝑜Kq[Q] +1 
 where Fo and F are the fluorescence intensities in the absence and presence of the quencher, 
respectively, Ksv is the Stern–Volmer quenching constant, Kq  is the bimolecular quenching 
constant and  𝜏𝑜 is the average lifetime of the fluorophore without the quencher which is 
approximately 10-8 s. From the equation, a plot of Fo/F against the concentration (Figure 46) of 
each of the complexes yielded a straight line whose slope was equal to the value of Ksv.  
 
 
Figure 47. Stern-Volmer plot for C2. 
 
A plot of Fo/F against the concentration of the complex C2 yielded a straight line with a 
slope of 21271 and an intercept of 1.02. Comparing the equation of the line to the Stern-Volmer 
equation,  Ksv equals the slope of the curve. The same approach was used to determine the Ksv 
values (Table 1) for the interaction between C4 and C6 with HSA. The Stern-Volmer quenching 
constant Ksv were in the range of 2.10 – 4.10 x 10
4 M-1. These calculated values are consistent 
with Ksv measures that have been reported for ruthenium(II) arene complexes. 
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 From the Stern-Volmer equation, it can be deduced that: 
𝜏𝑜Kq = Ksv, therefore, for C2 
𝜏𝑜Kq = 21271 
Kq = 21271/10
-8 
Kq = 2.1 x 10
12 M-1s-1 
A similar approach was followed to determine the bimolecular quenching constants (Kq) 
for both C4 and C6. The bimolecular quenching constants also ranged from 2.1 – 4.1 x 1012 M-1s-1 
and were found to be consistent with earlier reported bimolecular quenching constants for similar 
compounds. These observed constants are much greater than 2.0 × 1010 mol L−1 s −1,65, 68 the 
maximum value for dynamic quenching, indicating that the fluorescence quenching occurred via 
the static quenching mechanism. 
Kb and the number of binding sites “n” were calculated by generating a second plot from the 
modified Stern-Volmer equation: 
log(Fo-F)/F = n log[Q] + logKb.  
A graph of log(Fo-F)/F against log[Q] for complex C2  (Figure 48) also yielded a straight 
line with slope equal to “n”. The binding constants were calculated by finding the antilog of the 
intercept on the log(Fo-F)/F axis. Kb values calculated were also in the range of 3.6 -12.2 x 10
3 
M-1 (Table 1). These values were also consistent with similar Ru(II) piano-stool compounds 




Figure 48. Modified Stern-Volmer plot for C2. 
 
Table 2 summarizes the results of the interaction between complexes C2, C4 and C6. 
Complex Ksv (10
4 M-1) Kb (10
3 M-1) Kq (10
12 M-1 s-1) n 
C2 2.1 3.6 2.1 
 
0.83 
C4 4.1 12.2 4.1 
 
0.89 




Table 2. Stern-Volmer quenching constant, Ksv, Binding Constants, Kb and number of binding 
sites n determined at 37 oC and pH 7.4 
Complex C1 was not included presently due to inconsistencies in fluorescence quenching 
of HSA. The fluorescence intensities determined showed increased intensities in higher complex 
concentrations yielding a Stern-Volmer plot with coefficient of determination (R2) of 0.946. 

















So far in this research work, six Schiff base ligands and four ruthenium(II) compounds 
have been synthesized. The binding studies of three out of the four ruthenium(II) compounds 
synthesized have been achieved. The Stern-Volmer quenching constant  and the binding constant 
for the interaction between the complexes and HSA were found to be consistent with that already 
reported in literature. The bimolecular quenching constant also showed that, the quenching 
mechanism for the interaction between the complexes and HSA occurred through a static 
quenching mechanism. 
In the future, efforts will be made to carry out further experiments to establish the standard 
deviation of the results of complexes C2 C4 and C6 for the Stern-Volmer plots achieved so far. 
Additional experiment will evaluate other important drug properties, including the lipophilicity of 
the complexes and DNA interactions. The lipophilicity, which describes the ability of compounds 
to permeate cells would also be investigated to establish the ability of these compounds to enter 
cells.  It is also anticipated that, the compounds would be tested against different cell lines 
including MCF-7 breast cancer and A2780 ovarian cancer cell lines which earlier piano-stool 
ruthenium(II) compounds  have been tested against. This is to provide a comparative analysis of 
the efficacy of these compounds to already synthesized compounds such as RAPTA-C and 
RM175. Similar to RAPTA-C and RM175, the three compounds studied bind to HSA as shown in 
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Jamieson, S. M. F.; Hartinger, C. G. Organometallics 2014, 33, 5546−5553. 
71 
15.  Gossens, C.; Tavernelli, I; Rothlisberger. U. J. Am. Chem. Soc. 2008, 130, 10921–10928. 
16.  Chin, C. F.; Tian, Q.; Setyawati, M. I.  Fang, W.; Tan, E. S. Q.; Leong, D. T. Ang. W. H.     
J. Med. Chem. 2012, 55, 7571−7582.  
17.  Pal, M.; Nandi, U.; Mukherje, D. Eur. J. Med. Chem. 2018, 150, 419 - 445.  
18. Casini, A.; Mastrobuoni, G.; Terenghi, M.; Gabbiani, C.; Monzani, E.; Moneti G.;       
Casella, L.; Messori, L. J Biol. Inorg. Chem. 2007, 12, 1107–1117.   
19. Biancalana, L.; Batchelor, L. K.; Funaioli, T.; Zacchini, S.; Pampaloni, B G.; Dyson, P. 
J.; Marchetti, F. Inorg. Chem. 2018, 57, 6669−6685. 
20. Gasser, G.; Ott, I.; Metzler-Nolte, N. J. Med. Chem. 2011, 54, 3–25.  
21. Allardyce; S. C.; Dyson, P. J. Platium Metals Rev. 2001, 45, 62- 49. 
22.   DNA Intercalators. nptel.ac.in/courses. (accessed December 13, 2018) 
23.  Suss-Fink, G. Dalton Trans. 2010, 39, 1673–1688. 
 
24. Webb, M. I.; Wu, B; Jang, T; Chard, R. A.; Wong, E. W.; Wong, M. Q; Yapp, D. 
T.; Walsby, C. J. Chem. Eur. J. 2013, 19, 17031-17042 
25. Smithen, A. D.; Yin, H.; Beh, M. H. H.; Hetu, M.; Cameron, S. T.; McFarland, S. A.; 
Thompson, A. Inorg. Chem. 2017, 56, 4121−4132. 
26.  Guo, W.; Zheng, W.; Luo, Q.; Li, X.; Zhao, Y.; Xiong, S.; Wang, F. Inorg. Chem. 2013, 
52, 5328−5338.  
27. Du, Q.; Guo, L.; Tian, M. Ge, X.; Yang, Y.; Jian, X.; Xu, Z.; Tian, Z.; Liu, Z.  
Organomet. 2018, 37, 2880−2889. 
28. Debreczeni, J. E.; Bullock, N. A. G.; Atilla, E.; Williams, D. S.; Bregman, H.; Stefan K., 
Meggers, E. Angew. Chem. Int. Ed. 2006, 45,1580–1585. 
29. Vock, C. A.; Ang, W. H.; Scolaro, C.; Phillips, A. D.; Lagopoulos, L.; Juillerat- 
Jeanneret, L.  Sava, G.; Scopelliti, R.; Dyson, P. J. J. Med. Chem. 2007, 50, 2166-2175. 
72 
30. Levina, A.; Mitra, A; Lay, P. A. Metallomics, 2009, 1, 458–470.  
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APPENDIX A: SUPPLEMENTARY DATA OF CHAPTER TWO 
 














Figure A3. 1H NMR spectrum of 4-nitrophenylferrocene in DMSO-d6. 
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Figure A6. Positive mode ESI-HRMS spectrum of L4. 
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Figure A7. 1H NMR spectrum of ferrocenoyl azide in DMSO-d6. 
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Figure A8. 1H NMR spectrum of 2-(trimethylsilyl)ethylferrocenylcarbamate in CDCl3. 
 
Figure A9. 1H NMR Spectrum of a minoferrocene in CDCl3. 
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Figure A10. Positive mode ESI-HRMS spectrum of L5. 
 
 
SM - 101_190325112318 #1-20 RT: 0.01-0.27 AV: 20 NL: 8.88E8
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SM - 93 #2-39 RT: 0.05-1.02 AV: 38 NL: 5.79E8
T: FTMS + p ESI Full ms [66.7000-1000.0000]
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APPENDIX B: SUPPLEMENTARY DATA OF CHAPTER THREE 
 
Figure B1. UV-vis spectrum of 100 µM C2 in 10 % DMSO and PBS(aq) at pH 7.4 and 
temperature of 37 oC. 
 
Figure B2. UV-vis spectrum of 100 µM C4 in 10 % DMSO and PBS(aq) at pH 7.4 and 






































Figure B3. UV-vis spectrum of 100 µM C6 in 10 % DMSO and PBS(aq) at pH 7.4 and 




























APPENDIX C: SUPPLEMENTARY DATA OF CHAPTER FOUR 
 

























Figure C2. HSA fluorescence quenching by C4 at 37 oC and pH of 7.4. 
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Figure C4. Modified Stern-Volmer plot C4. 
 
 
Figure C5. Fluorescence quenching of C6. 
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Figure C6. Stern-Volmer plot for C6. 
 
Figure C7. Modified Stern-Volmer plot for C6. 
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